Abstract P4-14-12: Interim results from the first open-label, multicenter, phase IIIb study investigating the combination of pertuzumab with subcutaneous trastuzumab and a taxane in patients with HER2-positive metastatic breast cancer (SAPPHIRE)

2016 ◽  
Author(s):  
N Woodward ◽  
RH De Boer ◽  
A Redfern ◽  
M White ◽  
J Young ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Her2 Positive ◽  
Open Label ◽  
Multicenter Phase ◽  
Phase Iiib

An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 1028-1028 ◽  
Author(s):  
Binghe Xu ◽  
Jiayu Wang ◽  
Qingyuan Zhang ◽  
Yunjiang Liu ◽  
Ji Feng Feng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Her2 Positive ◽  
Open Label ◽  
Phase Ib ◽  
Multicenter Phase

scholarly journals An Open‐Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First‐Line HER2‐Positive Metastatic Breast Cancer

2013 ◽  
Vol 18 (6) ◽  
pp. 661-666 ◽  
Author(s):  
Francisco J. Esteva ◽  
Sandra X. Franco ◽  
Maura K. Hagan ◽  
Abenaa M. Brewster ◽  
Robert A. Somer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
First Line ◽  
Her2 Positive ◽  
Open Label ◽  
Safety Study
Sign in / Sign up

Export Citation Format

Share Document